acne scar acne scar
Conditions
Interventions
One side of face will be treated with air dissection using Air dissector device connecting with sterile 30G needle with 1-month interval for 3 sessions.,One side of face will be treated with 85% TCA C
Air dissecting ,TCA CROSS (TCA Chemical Reconstruction of Skin Scars)
Sponsors
Faculty of Medicine Siriraj hospital
Eligibility
Sex/Gender
All
Age
20 Years to 50 Years
Inclusion criteria
Inclusion criteria: 1. Male or female age 20-50 2. Moderate or severe acne scar
Exclusion criteria
Exclusion criteria: 1. Participants who are pregnant or breastfeeding. 2. Participants with a history of collagen-related disorders, such as Cushing syndrome or Ehlers-Danlos syndrome. 3. Participants with dermatitis, wounds, or skin infections on the facial area. 4. Participants with cancer, currently undergoing cancer treatment, or skin cancer in the area to be treated. 5. Participants with a history of immunodeficiency, including HIV infection or AIDS. 6. Participants with a history of allergy to anesthetics. 7. Participants with a history of abnormal photosensitivity. 8. Participants with a history of coagulation disorders or taking medications affecting blood coagulation, such as aspirin or anticoagulants. 9. Participants with a history of facial treatment using fillers, botulinum toxin injections, collagen biostimulators, platelet-rich plasma (PRP), or thread lifting within 6 months prior to participation in the research project. 10. Participants with a history of laser treatment for acne scars on the face within 6 months prior to participation in the research project. 11. Participants with a history of hypertrophic scars or skin rashes in the treatment area. 12. Participants with a history of acne treatment using isotretinoin within 6 months prior to participation in the research project. 13. Participants with a history of treatment using vitamin A derivatives within 3 months prior to participation in the research project. 14. Participants with a history of ischemic heart disease, cerebrovascular disease, renal failure, hepatic failure, coagulation disorders, anemia, or uncontrolled hypertension. 15. Participants with a history of psychiatric disorders. 16. Participants with any conditions deemed by the investigator to potentially compromise their safety if participating in the research project. 17. Participants who do not consent to photography for treatment evaluation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Volume depression baseline, 2nd treatment, 3rd treatment, 1-,3- and 6-month after 3rd treatment Antera 3D,Texture baseline, 2nd treatment, 3rd treatment, 1-,3- and 6-month after 3rd treatment Antera3D,Goodman and Baron's Quantitative Global Acne Scarring Grading System baseline, 2nd treatment, 3rd treatment, 1-,3- and 6-month after 3rd treatment Blinded evaluator | — |
Secondary
| Measure | Time frame |
|---|---|
| melanin index baseline, 2nd treatment, 3rd treatment, 1-,3- and 6-month after 3rd treatment Mexameter,Erythema index baseline, 2nd treatment, 3rd treatment, 1-,3- and 6-month after 3rd treatment Mexameter,Patient improvement scale baseline, 2nd treatment, 3rd treatment, 1-,3- and 6-month after 3rd treatment Patients self assessment,Safety baseline, 2nd treatment, 3rd treatment, 1-,3- and 6-month after 3rd treatment Adverse event | — |
Countries
Thailand
Contacts
Public ContactWoraphong Manuskiatti
Department of Dermatology, Faculty of medicine Siriraj hospital, Mahidol university
Outcome results
None listed